# A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

> **NCT00429091** · PHASE2 · COMPLETED · sponsor: **Abbott** · enrollment: 243 (actual)

## Conditions studied

- Attention-Deficit/Hyperactivity Disorder
- ADHD

## Interventions

- **DRUG:** ABT-894
- **DRUG:** atomoxetine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00429091
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2007-08
- **Final completion:** —
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2010-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00429091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00429091, "A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00429091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*